Translational Research Center for Gastrointestinal Disorders, KULeuven, Belgium.
Int J Obes (Lond). 2013 May;37(5):693-8. doi: 10.1038/ijo.2012.101. Epub 2012 Jul 31.
BACKGROUND/AIM: Liraglutide, a glucagon-like peptide-1 analog, induces weight loss. We investigated whether liraglutide affects gastric accommodation and satiation by measuring the intragastric pressure (IGP) during nutrient-drink consumption and using the barostat technique.
Ten healthy volunteers (HVs) were tested after placebo, 0.3, 0.6 or 1.2 mg liraglutide administration. IGP was studied during intragastric nutrient-drink (1.5 kcal ml(-1)) infusion (60 ml min(-1)), while the HVs scored their satiation on a graded scale until maximal satiation. In a separate session, isobaric distentions were performed using the barostat with stepwise increments of 2 mm Hg starting from minimal distending pressure, although HVs scored their perception; gastric volume was monitored 30 min before and until 60 min after ingestion of 200 ml of nutrient drink. Data are presented as mean±s.e.m. comparisons were performed with ANOVA (P<0.05 was significant).
During nutrient-drink infusion, IGP decreased with 4.1±0.7, 3.0±0.4, 2.1±0.3 and 2.6±0.4 mm Hg (placebo, 0.3, 0.6 and 1.2 mg liraglutide, respectively; P<0.05). The maximum-tolerated volume was not different, except after treatment with 1.2 mg liraglutide (695±135 ml) compared with placebo (1008±197 ml; P<0.05); however, 1.2 mg liraglutide induced nausea in all volunteers. In the barostat study, liraglutide did not affect the perception or compliance, but significantly decreased gastric accommodation to the meal (168±27 vs 78.8±36.4 ml after treatment with placebo and 0.6 mg liraglutide, respectively; P<0.05).
Although no effect on perception, compliance or satiation was observed, liraglutide inhibited gastric accommodation. Whether this effect is involved in the anorectic effect of liraglutide remains to be determined.
背景/目的:利拉鲁肽是一种胰高血糖素样肽-1 类似物,可引起体重减轻。我们通过测量营养饮料摄入期间的胃内压(IGP)并使用测压计技术来研究利拉鲁肽是否会影响胃容纳和饱腹感。
在安慰剂、0.3、0.6 或 1.2mg 利拉鲁肽给药后,对 10 名健康志愿者(HV)进行了测试。在胃内营养饮料(1.5kcal/ml)输注(60ml/min)期间研究了 IGP,同时 HV 对饱腹感进行了分级评分,直到达到最大饱腹感。在单独的会话中,使用测压计以 2mmHg 的逐步增量进行等压膨胀,从最小膨胀压力开始,但 HV 对其感知进行了评分;在摄入 200ml 营养饮料之前和之后的 30 分钟监测胃容量,直到 60 分钟。数据以平均值±标准误差表示,采用 ANOVA 进行比较(P<0.05 有统计学意义)。
在营养饮料输注期间,IGP 分别降低了 4.1±0.7、3.0±0.4、2.1±0.3 和 2.6±0.4mmHg(安慰剂、0.3、0.6 和 1.2mg 利拉鲁肽,分别;P<0.05)。最大耐受体积没有差异,但在给予 1.2mg 利拉鲁肽治疗后除外(695±135ml)与安慰剂(1008±197ml;P<0.05);然而,1.2mg 利拉鲁肽引起所有志愿者恶心。在测压计研究中,利拉鲁肽未影响感知或顺应性,但显著抑制了对膳食的胃容纳(分别为 168±27 和 78.8±36.4ml 治疗后安慰剂和 0.6mg 利拉鲁肽;P<0.05)。
尽管未观察到对感知、顺应性或饱腹感的影响,但利拉鲁肽抑制了胃容纳。这种作用是否涉及利拉鲁肽的厌食作用仍有待确定。